



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,116	05/05/2005	Sophie Poissonnier-Durieux	SERVIER 458 PCT	2435
25666	7590	10/31/2007		
THE FIRM OF HUESCHEN AND SAGE SEVENTH FLOOR, KALAMAZOO BUILDING 107 WEST MICHIGAN AVENUE KALAMAZOO, MI 49007			EXAMINER YOUNG, SHAWQUIA	
			ART UNIT 1626	PAPER NUMBER
			MAIL DATE 10/31/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/534,116	POISSONNIER-DURIEUX ET AL.	
	Examiner	Art Unit	
	Shawquia Young	1626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 August 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 20,22-33 and 35-37 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 35 and 36 is/are rejected.
- 7) ☒ Claim(s) 20,22-33 and 37 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>8/9/07</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claims 20, 22-33 and 35-37 are currently pending in the instant application.

Applicants have cancelled claims 21,34 and 38-40 in an amendment filed on August 9, 2007.

I. *Priority*

The instant application is a 371 of PCT/FR03/03278, filed on November 4, 2003 and claims benefit of Foreign Application FRANCE 02/13917, filed on November 7, 2002.

II. *Information Disclosure Statement*

The information disclosure statement filed August 9, 2007 fails to comply with 37 CFR 1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered.

III. *Response to Arguments*

Applicant's amendments, filed on August 9, 2007, have overcome the rejection of claims 37 and 40 under 35 USC 112, first paragraph as failing to comply with the enablement requirement and the objection to the oath or declaration as being defective

Art Unit: 1626

for not identifying the citizenship of each inventor. The above rejection has been withdrawn.

Applicants traverse the Examiner excluding heteroaryl and heteroaryl-(C₁-C₆)alkyl from the definition of R₁. Applicants argue that the fact that a heteroaryl group may be classified under different classes/subclasses does not demonstrate that one skilled in the chemical arts would recognize different heteroaryl groups to be structurally distinct. A "Field of Search" listing on nearly any US patent lists at least five or ten different class/subclass combinations, any number of which are relevant to the invention covered in that patent. Thus, a patent with claims directed to compound comprising different heteroaryl substituents may be assigned an original classification and be cross-referenced in other classes. Applicants further argue that under current Office Markush practice, the Office is obligated to expand, rather than narrow, restriction groups in the absence of identifying art which would demonstrate that patentably distinct groups exist.

The Examiner would like to point out that heteroaryl groups are classified differently because these compounds are considered structurally different. If the Examiner included heteroaryl groups in the definition of R₁ then the classes including 544, 546, 548, 549, etc. would also have to be searched. As mentioned in the previous Office Action, different search considerations are involved (i.e., class/subclass searches, databases searches, etc.) for each of the groups listed. The inventions are classified into classes 514, 544, 546, and 548. However, each Class 514, 544, 546 and 548 encompasses numerous patents and published applications. For instance, Class 514 contained 165,171 patents and published applications.

Restriction for examination purposes as indicated is proper because all the inventions listed in the previous Office action are independent or distinct for the reasons already given and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification;
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
- (d) the prior art applicable to one invention would not likely be applicable to another invention;
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

In the instant case, prior art applicable to the invention elected by applicant would not likely be applicable when R_1 is heteroaryl. The compound wherein R_1 is heteroaryl are not obvious variants of the compounds encompassed by Applicants elected invention.

The Examiner wants to remind Applicants that the instant application is a 371 does not follow Restriction guidelines for US filed applications under 35 USC 111. The Office is obligated to expand restriction groups in absence of identifying art which would

Art Unit: 1626

demonstrate that patentably distinct groups exist in US filed applications under 35 USC 111 not in application filed under 371. The lack of unity and the restriction requirement is deemed proper and is **MADE FINAL**.

Although there is non-elected subject matter present in the claims, the Examiner will rejoin the method claims for examination.

IV. Rejection(s)

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 35 and 36 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

In *In re Wands*, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. § 112, first paragraph, have been described. They are:

1. the nature of the invention,
2. the state of the prior art,

Art Unit: 1626

3. the predictability or lack thereof in the art,
4. the amount of direction or guidance present,
5. the presence or absence of working examples,
6. the breadth of the claims,
7. the quantity of experimentation needed, and
8. the level of the skill in the art.

The nature of the invention

Applicants are claiming a method of treating a living animal body afflicted with a disorder of the melatoninergetic system. See, for example, instant claim 36.

The state of the prior art and the predictability or lack thereof in the art

As mentioned in Applicants' specification on page 8, compounds of the instant invention have therapeutic properties for the various disorders including sleep disorders, severe depression, Alzheimer's disease, etc. Therefore Applicants' claims a method of treating a living animal body afflicted with a disorder of the melatoninergetic system including Alzheimer's disease, cardiovascular pathologies, psychotic disorders, diabetes, migraine, etc.

The state of the prior art, for example, is that the treatment of Alzheimer's disease, for example, remains highly unpredictable. It is the state of the art that there is no known cure or prevention for Alzheimer's disease and that there are only four medications available in the United States available to temporarily slow the early stages of Alzheimer's disease. The current drugs for the treatment of Alzheimer disease,

Art Unit: 1626

Aricept, Exelon, Reminyl and Cognex, treat early stages of Alzheimer's disease by delaying the breakdown of acetylcholine. Memantine, which blocks excess amounts of glutamate treats late stage Alzheimer's disease.

(<[URL:http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html](http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html)>.)

In addition, Layzer, Cecil Textbook of Medicine (article enclosed), states that "some degenerative diseases are difficult to classify because they involve multiple anatomic locations" (see page 2050). Alzheimer's disease has traditionally been very difficult or impossible to prevent or even to treat effectively with chemotherapeutic agents. (See e.g., the Cecil Textbook of Medicine, 20th edition (1996), Vol. 2, page 1994). There is no absolute predictability even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face.

The amount of direction or guidance present and the presence or absence of working examples

There is no evidence of record, which would enable the skilled artisan in the identification of the people who have the potential of becoming afflicted with the numerous diseases or disorders claimed herein. That a single class of compounds can be used to treat all melatoninerbic disorders. Applicants have not provided any competent evidence or disclosed tests that are highly predictive for the pharmaceutical use for treating or preventing any or all conditions by administering the instant claimed

Art Unit: 1626

compounds.

The breadth of the claims

The breadth of the claims is a method of treating a living animal body afflicted with a disorder of the melatoninergetic system.

The quantity of experimentation needed

The nature of the pharmaceutical arts is that it involves screening in vitro and in vivo to determine which compounds exhibit the desired pharmacological activities for each of the diseases and disorders instantly claimed. The quantity of experimentation needed would be undue when faced with the lack of direction and guidance present in the instant specification in regards to testing all diseases and disorders generically embraced in the claim language, and when faced with the unpredictability of the pharmaceutical art. Thus, factors such as "sufficient working examples", "the level of skill in the art" and predictability, etc. have been demonstrated to be sufficiently lacking in the instant case for the instant method claims.

The level of the skill in the art

Even though the level of skill in the pharmaceutical art is very high, based on the unpredictable nature of the invention and state of the prior art and lack of guidance and direction, one skilled in the art could not use the claimed invention without undue experimentation.

Applicants can overcome the above rejection by, for example, deleting the method claims.

V. Objections

Claim Objection-Non Elected Subject Matter

Claims 20, 22-33 and 35-37 are objected to as containing non-elected subject matter. To overcome this objection, Applicant should submit an amendment deleting the non-elected subject matter.

VI. Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Young whose telephone number is 571-272-9043. The examiner can normally be reached on 6:30 AM-3:00PM.

Art Unit: 1626

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Shawquid Young
Patent Examiner
Art Unit 1626, Group 1620
Technology Center 1600

KAMALA A. SAEED, PH.D.
PRIMARY EXAMINER

Joseph McKane
Supervisory Patent Examiner
Art Unit 1626, Group 1620
Technology Center 1600